Abstract
In a recent Transcranial Magnetic Stimulation (TMS) study, we demonstrated abnormally enhanced Short-Interval Intracortical Facilitation (SICF) in patients with Parkinson's Disease (PD). These abnormalities reflect increased glutamatergic transmission in primary motor cortex (M1). A short-term treatment with safinamide at 100 mg/day can restore SICF in PD by reducing glutamatergic transmission via blockade of voltage-gated sodium channels. We here examined the long-term effect of chronic treatment with safinamide 100 mg/day on SICF and other measures of M1 excitability and plasticity in PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
